Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | GHSR | Q92847 | 10/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482341 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2POLBGHSRRAD52ALDH1A1 | |
| SCHEMBL4485727 | 0.93 | SMN1; SMN2 (0.51) | SMN1; SMN2POLBGHSRRAD52ALDH1A1 | |
| SCHEMBL4485723 | 0.93 | SMN1; SMN2 (0.51) | SMN1; SMN2POLBGHSRRAD52ALDH1A1 | |
| SCHEMBL4481917 | 0.92 | SMN1; SMN2 (0.55) | SMN1; SMN2POLBGHSRALDH1A1LMNA | |
| SCHEMBL4481915 | 0.92 | SMN1; SMN2 (0.55) | SMN1; SMN2POLBGHSRALDH1A1LMNA | |
| SCHEMBL4504513 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2POLBGHSRALDH1A1LMNA | |
| SCHEMBL4504518 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2POLBGHSRALDH1A1LMNA | |
| SCHEMBL4504018 | 0.87 | SMN1; SMN2 (0.60) | SMN1; SMN2POLBGHSRALDH1A1LMNA | |
| SCHEMBL4504021 | 0.87 | SMN1; SMN2 (0.60) | SMN1; SMN2POLBGHSRALDH1A1LMNA | |
| SCHEMBL4488669 | 0.86 | SMN1; SMN2 (0.56) | SMN1; SMN2POLBGHSRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1527046-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | SMN1; SMN2 4006/4885POLB 4146/4885GHSR 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.